Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast crossover trial in severe uncontrolled asthma on ICS/LABA
2011-002101-29Phase 2Terminated
- Sponsor
- Nycomed
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roflumilast in asthma (2 arms), sponsored by Nycomed. Primary endpoint: Change in morning pre-dose trough FEV1. Started Jul 2011; status: terminated.
02
Drugs
roflumilast
03
Conditions
asthma
Beyond the preview
Go deeper on 2011-002101-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002101-29.